Dr. Paul Friedman of Dermatology & Laser Surgery Center in Houston, TX is conducting a clinical trial, using the Vbeam Prima laser, to improve facial flushing, redness, and the appearance of visible blood vessels, when used in combination with a topical prescription cream (RHOFADE™ (oxymetazoline HCl) Cream, 1%) for erythematotelangiectatic rosacea.
The study treatment by the laser device heats the tiny, broken blood vessels on the face and should improve flushing and redness. The study will try to determine if the areas treated with the laser and the topical prescription cream will have improved outcomes, compared to what would have been obtained with the topical prescription cream alone. The VBEAM PRIMA device used in this study was recently cleared by the Food and Drug Administration (FDA). The topical prescription cream used in the study, Allergen’s RHOFADE™ (Oxymetazoline Hydrochloride) 1% Cream is FDA-cleared for the topical treatment of persistent facial erythema associated with rosacea in adults.
The treatment is a series of three treatments, each of which take about 15 minutes. Treatments are performed in the office. The trial is free and includes reimbursement of $75 for each tube of RHOFADE not covered by insurance.
Study candidates must meet the following criteria:
- Are a healthy male or female of 18 to 75 years of age
- Have erythematotelangiectatic rosacea with clinician erythema assessment (CEA) and subject self-assessment (SSA) of “moderate” or “severe”
- Are not undergoing any form of treatment for active cancer or do not have a history of skin cancer or any other cancer on the face
- Not pregnant or planning to become pregnant during the study duration
For more information about trial participation, please contact us: 713-900-3900
Melasma study: laser combined with the tranexamic acid pill
Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 65 with moderate melasma or severe melasma. Participants will receive up to 5 monthly laser treatments to half the face and need to take a pill twice a day for 4 months. Follow up visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of up to $150 will be provided based on completed visits.
- Healthy male and female subjects between the ages 18 to 65
- Fitzpatrick skin types I through VI (all skin types)
- Moderate or severe melasma
- Willing to participate in study photography
- Able and willing to comply with all visit, treatment, and evaluation schedules
- Able to understand and provide written informed consent
- Pregnant, nursing women, current use of hormonal birth control medication or any hormonal therapy, or history of >2 spontaneous abortions
- Use of topical steroids on the face within 1 month of study enrollment, use of topical hydroquinone on the face within 3 months of study enrollment, laser or dermabrasion to the face within 6 months of study enrollment
- Regular use of tanning parlors, or occupation involving primarily outdoor activities
- Current treatment with blood thinning medications
- History of thrombosis, thrombophilia, or thromboembolic disease, such as deep vein thrombosis, pulmonary embolism and/or cerebral thrombosis, family history of thromboembolic disease
- History of seizures or known light sensitive seizure disorder, stroke, or subarachnoid hemorrhage
- History of kidney dysfunction
- History of cancer, or active smoking
- Significant cardiovascular or respiratory disease (end-stage congestive heart failure or chronic obstructive pulmonary disease)
- History of acquired disturbances of color vision
- Known allergy to tranexamic acid
- As per the investigator’s discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study
For More Information Contact The Research Department At
(212) 686-7306 or email@example.com